GB9921047D0 - Therapeutic antibody, immunogenic compositions & uses - Google Patents

Therapeutic antibody, immunogenic compositions & uses

Info

Publication number
GB9921047D0
GB9921047D0 GBGB9921047.8A GB9921047A GB9921047D0 GB 9921047 D0 GB9921047 D0 GB 9921047D0 GB 9921047 A GB9921047 A GB 9921047A GB 9921047 D0 GB9921047 D0 GB 9921047D0
Authority
GB
United Kingdom
Prior art keywords
immunogenic compositions
therapeutic antibody
antibody
therapeutic
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9921047.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Priority to GBGB9921047.8A priority Critical patent/GB9921047D0/en
Publication of GB9921047D0 publication Critical patent/GB9921047D0/en
Priority to CA002363637A priority patent/CA2363637A1/en
Priority to PCT/EP2000/001455 priority patent/WO2000050460A1/en
Priority to TR2001/02506T priority patent/TR200102506T2/en
Priority to JP2000601038A priority patent/JP2004538238A/en
Priority to MXPA01008613A priority patent/MXPA01008613A/en
Priority to BR0008963-0A priority patent/BR0008963A/en
Priority to PL00350993A priority patent/PL350993A1/en
Priority to AU26727/00A priority patent/AU2672700A/en
Priority to HU0200049A priority patent/HUP0200049A2/en
Priority to KR1020017010939A priority patent/KR20020007313A/en
Priority to EP00905073A priority patent/EP1155037A1/en
Priority to IL14502400A priority patent/IL145024A0/en
Priority to NZ513679A priority patent/NZ513679A/en
Priority to CN00806614A priority patent/CN1348466A/en
Priority to CZ20013082A priority patent/CZ20013082A3/en
Priority to ARP000100820A priority patent/AR029336A1/en
Priority to CO00013394A priority patent/CO5210906A1/en
Priority to NO20014130A priority patent/NO20014130L/en
Priority to HK02103724.5A priority patent/HK1044004A1/en
Priority to US10/304,443 priority patent/US20030170229A1/en
Priority to US11/005,794 priority patent/US20050214285A1/en
Ceased legal-status Critical Current

Links

GBGB9921047.8A 1999-02-25 1999-09-07 Therapeutic antibody, immunogenic compositions & uses Ceased GB9921047D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
CZ20013082A CZ20013082A3 (en) 1999-02-25 2000-02-22 Peptide
KR1020017010939A KR20020007313A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
IL14502400A IL145024A0 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
TR2001/02506T TR200102506T2 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from Ige's C-epsilon-2 domain
JP2000601038A JP2004538238A (en) 1999-02-25 2000-02-22 Epitope or mimotope derived from the C-epsilon-2 domain of IgE, antagonists and therapeutic uses thereof
MXPA01008613A MXPA01008613A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
BR0008963-0A BR0008963A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the ige dec-epsilon-2 domain, antagonists thereof, and their therapeutic uses
PL00350993A PL350993A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
AU26727/00A AU2672700A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
HU0200049A HUP0200049A2 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
CA002363637A CA2363637A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
EP00905073A EP1155037A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists therof, and their therapeutic uses
PCT/EP2000/001455 WO2000050460A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
NZ513679A NZ513679A (en) 1999-02-25 2000-02-22 Epitodes or mimotopes derived from the C-epsilon-2 domain of IgE, antagonists thereof, and their therapeutic uses
CN00806614A CN1348466A (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2-domain of IgE, antagonists thereof, and their therapeutic uses
CO00013394A CO5210906A1 (en) 1999-02-25 2000-02-25 IMUNOGENS CONTAINING PEPTIDES FROM DOMINO CE2 DE IgE FOR THE TREATMENT AND PREVENTION OF ALLERGIC DISEASES
ARP000100820A AR029336A1 (en) 1999-02-25 2000-02-25 USEFUL PEPTIDES TO PREPARE MEDICINES FOR THE TREATMENT, PREVENTION OR IMPROVEMENT OF ALLERGIC STATES, IMMUNOGENS, EPITHOPES AND MIMOTOPES, VACCINES, LIGENDS, PHARMACEUTICAL COMPOSITIONS; USE OF THE PEPTIDES, OF THE LIGANDS IN THE PREPARATION OF MEDICINES; PROCESS TO PREPARE VACCINES AND PR
NO20014130A NO20014130L (en) 1999-02-25 2001-08-24 Epitopes or mimotopes derived from the C <epsilon> 2 domain of IgE, its antagonists and their therapeutic uses
HK02103724.5A HK1044004A1 (en) 1999-02-25 2002-05-16 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
US10/304,443 US20030170229A1 (en) 1999-02-25 2002-11-26 Vaccine
US11/005,794 US20050214285A1 (en) 1999-03-29 2004-12-07 Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses

Publications (1)

Publication Number Publication Date
GB9921047D0 true GB9921047D0 (en) 1999-11-10

Family

ID=10860444

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9921047.8A Ceased GB9921047D0 (en) 1999-02-25 1999-09-07 Therapeutic antibody, immunogenic compositions & uses

Country Status (1)

Country Link
GB (1) GB9921047D0 (en)

Similar Documents

Publication Publication Date Title
ZA200201810B (en) Combined vaccine compositions.
EG24742A (en) Vaccine composition.
HK1105581A1 (en) Vaccine composition
MXPA03008961A (en) Vaccine composition.
HK1045650A1 (en) Pharmaceutical composition.
ZA200004956B (en) Vaccine composition.
HK1042845A1 (en) Cosmetic composition.
GB9910812D0 (en) Vaccine composition
ZA200108248B (en) Antiperspirant compositions.
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200000857B (en) Pharmaceutical composition.
AU2544300A (en) Immunogenic compounds
IL152533A0 (en) NOVEL FORMULATIONS OF alpha-2,4-DISULFOPHENYL-N-TERTBUTYLNITRONE
AU2001267541A1 (en) Vaccine composition
MXPA01010701A (en) Vaccine.
GB9921047D0 (en) Therapeutic antibody, immunogenic compositions &amp; uses
AU2913600A (en) Immunogenic compounds
GB9921347D0 (en) Novel immunogenic compositions
GB9910538D0 (en) Therapeutic antibody, Immunogenic compositions ansd uses
AU1101701A (en) Vaccine compositions
GB9910537D0 (en) Therapeutic antibody, Immunogenic compositions and uses
GB9929434D0 (en) Novel vaccine composition
ZA200203986B (en) Vaccine compositions.
GB9906696D0 (en) Vaccine composition
GB9906694D0 (en) Vaccine composition

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)